Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.68 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.68 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.68 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.68 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030496 | 0.84 | DYRK1A (0.72) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL3818537 | 0.81 | DYRK1A (0.68) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL29488162 | 0.81 | GSK3B (1.00) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL29534011 | 0.81 | DYRK1A (0.68) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL573402 | 0.81 | GSK3B (1.00) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL28230580 | 0.80 | CLK1 (0.67) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL25034150 | 0.78 | TUBB4A (0.68) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL7496465 | 0.78 | DYRK1A (0.63) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL20691186 | 0.78 | EIF2AK2 (0.67) | DYRK1AGSK3BCLK1CDK5CDK5R1 | |
| SCHEMBL145566 | 0.77 | GSK3B (0.70) | DYRK1AGSK3BCLK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | DYRK1A 321/4885GSK3B 110/4885CLK1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.